Bronchoalveolar lavage fluid (BALF): Clinical applications for present and future
-
GRAPHICAL ABSTRACT
DownLoad:
Full size image
-
PUBLIC SUMMARY
-
Bronchoalveolar lavage fluid has significant clinical application potential.
Bronchoalveolar lavage fluid detection encompasses cytology, microbiology, and molecular biology.
The omics era facilitates clinical practice based on bronchoalveolar lavage fluid.
-
-
ABSTRACT
Lungs are exposed to a wide range of complex internal and external environmental factors, creating a complex pulmonary microenvironment that remains challenging to detect and interpret. Bronchoalveolar lavage fluid (BALF) contains an abundance of cells, microorganisms, and active substances, thus is considered to be a clinically promising body fluid detection substance that is representative of the pulmonary microenvironment. The combination of experimental strategies with emerging omics technologies has advanced the identification and interpretation of microscopic components in BALF, underscoring its applications in clinical detection. In summary, this review provides a systematic overview of the development understanding of BALF, discusses its possible applications in clinical diagnosis, prediction, and intervention, and highlights the role of emerging omics technologies in deciphering BALF. -
-
REFERENCES
[1] Zepp J.A. and Morrisey E.E. (2019). Cellular crosstalk in the development and regeneration of the respiratory system. Nat. Rev. Mol. Cell Biol. 20:551−566. DOI:10.1038/s41580-019-0141-3 [2] Zepp J.A., Morley M.P., Loebel C., et al. (2021). Genomic, epigenomic, and biophysical cues controlling the emergence of the lung alveolus. Science (New York, N.Y.) 371:eabc3172. DOI:10.1126/science.abc3172 [3] Sapoval B., Kang M. and Dinh-Xuan A.T. (2020). Modeling of gas exchange in the lungs. Compr. Physiol. 11:1289−1314. DOI:10.1002/cphy.c190019 [4] Melbourne C.A., Mesut Erzurumluoglu A., Shrine N., et al. (2022). Genome-wide gene-air pollution interaction analysis of lung function in 300,000 individuals. Environ. Int. 159:107041. DOI:10.1016/j.envint.2021.107041 [5] Feng G., Xia J., Wang X., et al. (2024). Assessing the disease burden of air pollution on children and adolescents in china from 1990 to 2019. Innov. Med. 2:100057. DOI:10.59717/j.xinn-med.2024.100057 [6] Olesiejuk K. and Chałubiński M. (2023). How does particulate air pollution affect barrier functions and inflammatory activity of lung vascular endothelium. Allergy 78:629−638. DOI:10.1111/all.15630 [7] Cai M., Su B., Hu G., et al. (2024). Long term exposure to PM2.5 chemical components associated with prevalence of cardiovascular diseases in China. Innov. Med. 2 :100077. DOI: 10.59717/j.xinn-med.2024.100077 [8] Unger S.A. and Bogaert D. (2017). The respiratory microbiome and respiratory infections. J. Infect. 74 Suppl 1 :S84-S88. DOI: 10.1016/S0163-4453(17)30196-2 [9] Wang C.C., Prather K.A., Sznitman J., et al. (2021). Airborne transmission of respiratory viruses. Science (New York, N.Y.) 373:eabd9149. DOI:10.1126/science.abd9149 [10] Falagas M.E., Agrafiotis M., Athanassa Z., et al. (2008). Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev. Anti-Infect. Ther. 6:447−452. DOI:10.1586/14787210.6.4.447 [11] Hill W., Lim E.L., Weeden C.E., et al. (2023). Lung adenocarcinoma promotion by air pollutants. Nature 616:159−167. DOI:10.1038/s41586-023-05874-3 [12] Ravaglia C., Doglioni C., Chilosi M., et al. (2022). Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-cov-2 infection. Eur. Respir. J. 60:2102411. DOI:10.1183/13993003.02411-2021 [13] Lim K., Donovan A.P.A., Tang W., et al. (2023). Organoid modeling of human fetal lung alveolar development reveals mechanisms of cell fate patterning and neonatal respiratory disease. Cell Stem Cell 30:20−37. DOI:10.1016/j.stem.2022.11.013 [14] Youk J., Kim T., Evans K.V., et al. (2020). Three-dimensional human alveolar stem cell culture models reveal infection response to SARS-cov-2. Cell Stem Cell 27:905−919. DOI:10.1016/j.stem.2020.10.004 [15] Mei J., Liu X., Tian H.X., et al. (2024). Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy. Clin. Transl. Med. 14:e1656. DOI:10.1002/ctm2.1656 [16] Liao M., Liu Y., Yuan J., et al. (2020). Single-cell landscape of bronchoalveolar immune cells in patients with covid-19. Nat. Med. 26:842−844. DOI:10.1038/s41591-020-0901-9 [17] Li T., Liu Y., Zhang W., et al. (2020). A rapid liquid biopsy of lung cancer by separation and detection of exfoliated tumor cells from bronchoalveolar lavage fluid with a dual-layer "perfect" filter system. Theranostics 10:6517−6529. DOI:10.7150/thno.44274 [18] Darlington P., Kullberg S., Eklund A., et al. (2020). Subpopulations of cells from bronchoalveolar lavage can predict prognosis in sarcoidosis. Eur. Respir. J. 55:1901450. DOI:10.1183/13993003.01450-2019 [19] Masuhiro K., Tamiya M., Fujimoto K., et al. (2022). Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of pd-1 blockade in lung cancer. JCI Insight 7:e157915. DOI:10.1172/jci.insight.157915 [20] Liao L. and Yang G. (2021). Clinical significance of cellular immunity function and inflammatory factors assays in alveolar lavage fluid for severe covid-19 pneumonia. J. Med. Virol. 93:2979−2987. DOI:10.1002/jmv.26827 [21] Daniele R.P., Elias J.A., Epstein P.E., et al. (1985). Bronchoalveolar lavage: Role in the pathogenesis, diagnosis, and management of interstitial lung disease. Ann. Intern. Med. 102:93−108 [22] Xu P., Tang P., Song H., et al. (2019). The incremental value of bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in a high-burden urban setting. J. Infect. 79:24−29. DOI:10.1016/j.jinf.2019.05.009 [23] Chen S., Kang Y., Li D., et al. (2022). Diagnostic performance of metagenomic next-generation sequencing for the detection of pathogens in bronchoalveolar lavage fluid in patients with pulmonary infections: systematic review and meta-analysis. Int. J. Infect. Dis. 122:867−873. DOI:10.1016/j.ijid.2022.07.054 [24] Ding W., Yue W. and Fu Y. (2010). [The current research feature and prospect of bronchoalveolar lavage in diagnosing lung cancer]. Chinese Journal of Lung Cancer 13:370−374. DOI:10.3779/j.issn.1009-3419.2010.04.19 [25] Niederman M.S. (2010). The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. Clin. Infect. Dis. 51 Suppl 1 :S93-S99. DOI: 10.1086/653055 [26] Miao Q., Ma Y., Wang Q., et al. (2018). Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice. Clin. Infect. Dis. 67:S231−S240. DOI:10.1093/cid/ciy693 [27] Ewig S., Torres A., Angeles Marcos M., et al. (2002). Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur. Respir. J. 20:1254−1262. DOI:10.1183/09031936.02.01942001 [28] Tian H.X., Mei J., Cao L., et al. (2023). Disruption of iron homeostasis to induce ferroptosis with albumin-encapsulated pt(iv) nanodrug for the treatment of non-small cell lung cancer. Small 19:e2206688. DOI:10.1002/smll.202206688 [29] Zöllner F. (1965). Gustav Killian, father of bronchoscopy. Arch. Otolaryngol. 82:656−659. [30] Boyd A.D. (1994). Chevalier Jackson: The father of American bronchoesophagoscopy. Ann. Thorac. Surg. 57:502−505. [31] Ikeda S., Tsuboi E., Ono R., et al. (2010). Flexible bronchofiberscope. Jpn. J. Clin. Oncol. 40:e55−e64. DOI:10.1093/jjco/hyq114 [32] Ikeda S., Yanai N. and Ishikawa S. (1968). Flexible bronchofiberscope. The Keio Journal of Medicine 17:1−16. [33] Fujino M.A., Morozumi A., Nakamura T., et al. (1994). Electronic endoscopy in perspective. J. Gastroenterol. 29 Suppl 7 :85-90. [34] Demling L. and Hagel H.J. (1985). Video endoscopy. Fundamentals and problems. Endoscopy 17:167−169. DOI:10.1055/s-2007-1018491 [35] Classen M. and Phillip J. (1984). Electronic endoscopy of the gastrointestinal tract. Initial experience with a new type of endoscope that has no fiberoptic bundle for imaging. Endoscopy 16:16−19. DOI:10.1055/s-2007-1018518 [36] Andersen H.A. and Fontana R.S. (1972). Transbronchoscopic lung biopsy for diffuse pulmonary diseases: Technique and results in 450 cases. Chest 62:125−128. DOI:10.1378/chest.62.2.125 [37] Reynolds H.Y. and Newball H.H. (1974). Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. The Journal of Laboratory and Clinical Medicine 84:559−573. [38] Springmeyer S.C., Hackman R., Carlson J.J., et al. (1983). Bronchiolo-alveolar cell carcinoma diagnosed by bronchoalveolar lavage. Chest 83:278−279. DOI:10.1378/chest.83.2.278 [39] Goel S., Yeshvanth S.K., Asnani R., et al. (2022). Accuracy of bronchial cytological diagnosis in lung lesions in comparison with histopathology. J. Cytol. 39:163−168. DOI:10.4103/joc.joc_44_22 [40] Bezel P., Valaperti A., Steiner U., et al. (2021). Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis. Cancer Immunol. Immunother. 70:1867−1876. DOI:10.1007/s00262-020-02798-z [41] Tanaka Y., Nakai T., Suzuki A., et al. (2023). Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma. Cancer Immunol. Immunother. 72:2205−2215. DOI:10.1007/s00262-023-03393-8 [42] Meyer K.C., Raghu G., Baughman R.P., et al. (2012). An official american thoracic society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med. 185:1004−1014. DOI:10.1164/rccm.201202-0320ST [43] Frye B.C., Schupp J.C., Rothe M.E., et al. (2020). The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals. J. Intern. Med. 287:54−65. DOI:10.1111/joim.12973 [44] Chen C., Liu F., Quan S., et al. (2023). Microplastics in the bronchoalveolar lavage fluid of chinese children: Associations with age, city development, and disease features. Environ. Sci. Technol. 57:12594−12601. DOI:10.1021/acs.est.3c01771 [45] Catinon M., Cavalin C., Chemarin C., et al. (2018). Sarcoidosis, inorganic dust exposure and content of bronchoalveolar lavage fluid: the minasarc pilot study. Sarcoidosis Vasc. Diffuse Lung Dis. 35:327−332. DOI:10.36141/svdld.v35i4.7058 [46] Hastie A.T., Bishop A.C., Khan M.S., et al. (2024). Protein-protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma. Clin. Exp. Allergy 54:265−277. DOI:10.1111/cea.14447 [47] Mayr C.H., Simon L.M., Leuschner G., et al. (2021). Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Mol. Med. 13:e12871. DOI:10.15252/emmm.202012871 [48] Stjärne Aspelund A., Hammarström H., Inghammar M., et al. (2018). Heparin-binding protein, lysozyme, and inflammatory cytokines in bronchoalveolar lavage fluid as diagnostic tools for pulmonary infection in lung transplanted patients. Am. J. Transplant. 18:444−452. DOI:10.1111/ajt.14458 [49] Man W.H., de Steenhuijsen Piters W.A.A. and Bogaert D. (2017). The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15:259−270. DOI:10.1038/nrmicro.2017.14 [50] Thibeault C., Suttorp N. and Opitz B. (2021). The microbiota in pneumonia: from protection to predisposition. Sci. Transl. Med. 13:eaba501. DOI:10.1126/scitranslmed.aba0501 [51] Wypych T.P., Wickramasinghe L.C. and Marsland B.J. (2019). The influence of the microbiome on respiratory health. Nat. Immunol. 20:1279−1290. DOI:10.1038/s41590-019-0451-9 [52] Xiang L. and Meng X. (2022). Emerging cellular and molecular interactions between the lung microbiota and lung diseases. Crit. Rev. Microbiol. 48:577−610. DOI:10.1080/1040841X.2021.1992345 [53] Natalini J.G., Singh S. and Segal L.N. (2023). The dynamic lung microbiome in health and disease. Nat. Rev. Microbiol. 21:222−235. DOI:10.1038/s41579-022-00821-x [54] de Blic J., Midulla F., Barbato A., et al. (2000). Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. Eur. Respir. J. 15:217−231. DOI:10.1183/09031936.00.15121700 [55] Du Rand I.A., Blaikley J., Booton R., et al. (2013). British thoracic society guideline for diagnostic flexible bronchoscopy in adults: accredited by nice. Thorax 68 Suppl 1 :i1-i44. DOI: 10.1136/thoraxjnl-2013-203618 [56] Qu J., Zhou J. and Yu Y. (2017). [Chinese expert consensus on pathogen detection of bronchoalveolar lavage for pulmonary infectious diseases (2017)]. Chinese Journal of Tuberculosis and Respiratory Diseases 40:578−583. DOI:10.3760/cma.j.issn.1001-0939.2017.08.007 [57] Connett G.J. (2000). Bronchoalveolar lavage. Paediatr. Respir. Rev. 1:52−56. DOI:10.1053/prrv.2000.0007 [58] Zhou D., Wu M., Xu S., et al. (2020). [Consensus of chinese experts on morphological examination of bronchoalveolar lavage fluid cells (2020)]. Journal of Modern Laboratory Medicine 35:4−8. DOI:10.3969/j.issn.1671-7414.2020.06.002 [59] Xiao G., Cai Z., Guo Q., et al. (2022). Insights into the unique lung microbiota profile of pulmonary tuberculosis patients using metagenomic next-generation sequencing. Microbiol. Spectr. 10:e190121. DOI:10.1128/spectrum.01901-21 [60] Zhang H., Deng D., Li S., et al. (2023). Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer. Cancer Biol. Med. 21:230−251. DOI:10.20892/j.issn.2095-3941.2023.0381 [61] Kadota N., Nakahira N., Miyauchi M., et al. (2022). Usefulness of bronchoalveolar lavage (BAL) in the diagnosis of pulmonary alveolar proteinosis. QJM 115:767−768. DOI:10.1093/qjmed/hcac168 [62] Patolia S., Tamae Kakazu M., Chami H.A., et al. (2020). Bronchoalveolar lavage lymphocytes in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann. Am. Thorac. Soc. 17:1455−1467. DOI:10.1513/AnnalsATS.202005-420OC [63] Barcik W., Boutin R.C.T., Sokolowska M., et al. (2020). The role of lung and gut microbiota in the pathology of asthma. Immunity 52:241−255. DOI:10.1016/j.immuni.2020.01.007 [64] Sommariva M., Le Noci V., Bianchi F., et al. (2020). The lung microbiota: Role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell. Mol. Life Sci. 77:2739−2749. DOI:10.1007/s00018-020-03452-8 [65] Gosens R., Hiemstra P.S., Adcock I.M., et al. (2020). Host-microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease. The Eur. Respir. J. 56:1902320. DOI:10.1183/13993003.02320-2019 [66] Scholte J.B.J., van Dessel H.A., Linssen C.F.M., et al. (2014). Endotracheal aspirate and bronchoalveolar lavage fluid analysis: Interchangeable diagnostic modalities in suspected ventilator-associated pneumonia. J. Clin. Microbiol. 52:3597−3604. DOI:10.1128/JCM.01494-14 [67] Zhang R., Wu Y., Deng G., et al. (2022). Value of sputum gram stain, sputum culture, and bronchoalveolar lavage fluid gram stain in predicting single bacterial pathogen among children with community-acquired pneumonia. BMC Pulm. Med. 22:427. DOI:10.1186/s12890-022-02234-1 [68] Zhao D., Yang X., Chen Q., et al. (2012). A modified acid-fast staining method for rapid detection of mycobacterium tuberculosis. J. Microbiol. Methods 91:128−132. DOI:10.1016/j.mimet.2012.07.024 [69] Doering T.L. (2009). How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in cryptococcus neoformans. Annu. Rev. Microbiol. 63:223−247. DOI:10.1146/annurev.micro.62.081307.162753 [70] De Pauw B., Walsh T.J., Donnelly J.P., et al. (2008). Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (eortc/msg) consensus group. Clin. Infect. Dis. 46:1813−1821. DOI:10.1086/588660 [71] Rohner P., Jacomo V., Studer R., et al. (2009). Detection of pneumocystis jirovecii by two staining methods and two quantitative PCR assays. Infection 37:261−265. DOI:10.1007/s15010-008-8027-x [72] Liu X., Hou X., Gao L., et al. (2018). Indicators for prediction of mycobacterium tuberculosis positivity detected with bronchoalveolar lavage fluid. Infect. Dis. Poverty 7:22. DOI:10.1186/s40249-018-0403-x [73] Ashitani J., Kumamoto K., Matsukura S. (2000). Paragonimiasis westermani with multifocal lesions in lungs and skin. Intern. Med. 39:433−436. DOI:10.2169/internalmedicine.39.433 [74] S Pavia C. and M Plummer M. (2021). The evolution of rapid antigen detection systems and their application for covid-19 and other serious respiratory infectious diseases. J. Microbiol. Immunol. Infect. 54:776−786. DOI:10.1016/j.jmii.2021.06.003 [75] The committee of chinese laboratory medical education, chinese thoracic society of the chinese medical association. (2023). [Expert consensus on nucleic acid of amplification techniques test for the diagnosis of pathogens in adult respiratory tract infections (2023)]. Medical Journal of Peking Union Medical College Hospital 14:959−971. DOI: 10. 12290 / xhyxzz. 2023-0338. DOI:10.12290/xhyxzz.2023-0338 [76] Goodwin S., Mcpherson J.D. and Mccombie W.R. (2016). Coming of age: Ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17:333−351. DOI:10.1038/nrg.2016.49 [77] Deng W., Xu H., Wu Y., et al. (2022). Diagnostic value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in pediatric pneumonia. Front. Cell. Infect. Microbiol. 12:950531. DOI:10.3389/fcimb.2022.950531 [78] Wyres K.L., Lam M.M.C. and Holt K.E. (2020). Population genomics of klebsiella pneumoniae. Nat. Rev. Microbiol. 18:344−359. DOI:10.1038/s41579-019-0315-1 [79] Wyres K.L. and Holt K.E. (2018). Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria. Curr. Opin. Microbiol. 45:131−139. DOI:10.1016/j.mib.2018.04.004 [80] Sanchez G.V., Master R.N., Clark R.B., et al. (2013). Klebsiella pneumoniae antimicrobial drug resistance, united states, 1998-2010. Emerg. Infect. Dis. 19:133−136. DOI:10.3201/eid1901.120310 [81] Zhang S., Abbas M., Rehman M.U., et al. (2020). Dissemination of antibiotic resistance genes (args) via integrons in escherichia coli: A risk to human health. Environ. Pollut. 266:115260. DOI:10.1016/j.envpol.2020.115260 [82] Tang Z., Zhang Y., Xiao S., et al. (2022). Insight into the impacts and mechanisms of ketone stress on the antibiotic resistance in Escherichia coli. Environ. Sci. Pollut. Res. Int. 29:83746−83755. DOI:10.1007/s11356-022-21600-4 [83] Boolchandani M., D'Souza A.W. and Dantas G. (2019). Sequencing-based methods and resources to study antimicrobial resistance. Nat. Rev. Genet. 20:356−370. DOI:10.1038/s41576-019-0108-4 [84] Vehreschild M.J.G.T., Hamprecht A., Peterson L., et al. (2014). A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J. Antimicrob. Chemother. 69:3387−3392. DOI:10.1093/jac/dku305 [85] Ha Y.E., Kang C., Cha M.K., et al. (2013). Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int. J. Antimicrob. Agents 42:403−409. DOI:10.1016/j.ijantimicag.2013.07.018 [86] Margalit I., Lebeaux D., Tishler O., et al. (2021). How do I manage nocardiosis. Clin. Microbiol. Infect. 27:550−558. DOI:10.1016/j.cmi.2020.12.019 [87] Bickett T.E. and Karam S.D. (2020). Tuberculosis-cancer parallels in immune response regulation. Int. J. Mol. Sci. 21:6136. DOI:10.3390/ijms21176136 [88] Fol M., Koziński P., Kulesza J., et al. (2021). Dual nature of relationship between mycobacteria and cancer. International J. Mol. Sci. 22:8332. DOI:10.3390/ijms22158332 [89] Erkes D.A., Wilski N.A. and Snyder C.M. (2017). Intratumoral infection by cmv may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity. Hum. Vaccin. Immunother. 13:1778−1785. DOI:10.1080/21645515.2017.1331795 [90] Cobbs C. (2019). Cytomegalovirus is a tumor-associated virus: Armed and dangerous. Curr. Opin. Virol. 39:49−59. DOI:10.1016/j.coviro.2019.08.003 [91] Lin Y., Lau H.C., Liu Y., et al. (2022). Altered mycobiota signatures and enriched pathogenic aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology 163:908−921. DOI:10.1053/j.gastro.2022.06.038 [92] Ullmann A.J., Aguado J.M., Arikan-Akdagli S., et al. (2018). Diagnosis and management of aspergillus diseases: executive summary of the 2017 escmid-ecmm-ers guideline. Clin. Microbiol. Infect. 24 Suppl 1 :e1-e38. DOI: 10.1016/j.cmi.2018.01.002 [93] Schmalzle S.A., Buchwald U.K., Gilliam B.L., et al. (2016). Cryptococcus neoformans infection in malignancy. Mycoses 59:542−552. DOI:10.1111/myc.12496 [94] Nematollahi S. and Dioverti-Prono V. (2020). Cryptococcal infection in haematologic malignancies and haematopoietic stem cell transplantation. Mycoses 63:1033−1046. DOI:10.1111/myc.13153 [95] Fillatre P., Decaux O., Jouneau S., et al. (2014). Incidence of pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am. J. Med. 127:1211−1242. DOI:10.1016/j.amjmed.2014.07.010 [96] Maschmeyer G., Helweg-Larsen J., Pagano L., et al. (2016). ECIL guidelines for treatment of pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J. Antimicrob. Chemother. 71:2405−2413. DOI:10.1093/jac/dkw158 [97] Classen A.Y., Henze L., von Lilienfeld-Toal M., et al. (2021). Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the infectious diseases working party of the german society of hematology and medical oncology (agiho/dgho). Ann. Hematol. 100:1603−1620. DOI:10.1007/s00277-021-04452-9 [98] Pena T. and Klesney-Tait J. (2017). Mycobacterial infections in solid organ and hematopoietic stem cell transplantation. Clin. Chest. Med. 38:761−770. DOI:10.1016/j.ccm.2017.07.011 [99] Russo R.L., Dulley F.L., Suganuma L., et al. (2010). Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int. J. Infect. Dis. 14 Suppl 3 :e187-e191. DOI: 10.1016/j.ijid.2009.08.001 [100] Haidar G., Boeckh M. and Singh N. (2020). Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J. Infect. Dis. 221:S23−S31. DOI:10.1093/infdis/jiz454 [101] De La Cruz O. and Silveira F.P. (2017). Respiratory fungal infections in solid organ and hematopoietic stem cell transplantation. Clin. Chest Med. 38:727−739. DOI:10.1016/j.ccm.2017.07.013 [102] Sprute R., Nacov J.A., Neofytos D., et al. (2023). Antifungal prophylaxis and pre-emptive therapy: When and how. Mol. Aspects. Med. 92:101190. DOI:10.1016/j.mam.2023.101190 [103] Trapnell B.C., Whitsett J.A. and Nakata K. (2003). Pulmonary alveolar proteinosis. N. Engl. J. Med. 349:2527−2539. DOI:10.1056/NEJMra023226 [104] De Giacomi F., Vassallo R., Yi E.S., et al. (2018). Acute eosinophilic pneumonia. Causes, diagnosis, and management. Am. J. Respir. Crit. Care Med. 197:728−736. DOI:10.1164/rccm.201710-1967CI [105] Newman L.S., Mroz M.M., Balkissoon R., et al. (2005). Beryllium sensitization progresses to chronic beryllium disease: A longitudinal study of disease risk. Am. J. Respir. Crit. Care Med. 171:54−60. DOI:10.1164/rccm.200402-190OC [106] Grommes J. and Soehnlein O. (2011). Contribution of neutrophils to acute lung injury. Mol. Med. 17:293−307. DOI:10.2119/molmed.2010.00138 [107] Reisinger A.C., Hatzl S., Prattes J., et al. (2024). Soluble urokinase plasminogen activator receptor (supar) in bronchoalveolar fluid and blood in critically ill patients-a prospective cohort study. Infection 52:249−252. DOI:10.1007/s15010-023-02127-3 [108] Caparrós-Martín J.A., Saladie M., Agudelo-Romero S.P., et al. (2023). Detection of bile acids in bronchoalveolar lavage fluid defines the inflammatory and microbial landscape of the lower airways in infants with cystic fibrosis. Microbiome 11:132. DOI:10.1186/s40168-023-01543-9 [109] Mccarthy C., Carey B.C., Trapnell B.C. (2022). Autoimmune pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 205:1016−1035. DOI:10.1164/rccm.202112-2742SO [110] Wicks I.P. and Roberts A.W. (2016). Targeting GM-CSF in inflammatory diseases. Nat. Rev. Rheumatol. 12:37−48. DOI:10.1038/nrrheum.2015.161 [111] Church D.L., Cerutti L., Gürtler A., et al. (2020). Performance and application of 16s rRNA gene cycle sequencing for routine identification of bacteria in the clinical microbiology laboratory. Clin. Microbiol. Rev. 33:e19−e53. DOI:10.1128/CMR.00053-19 [112] Chiu C.Y. and Miller S.A. (2019). Clinical metagenomics. Nat. Rev. Genet. 20:341−355. DOI:10.1038/s41576-019-0113-7 [113] Liu Y., Qin Y., Chen T., et al. (2021). A practical guide to amplicon and metagenomic analysis of microbiome data. Protein Cell 12:315−330. DOI:10.1007/s13238-020-00724-8 [114] Eisenhofer R., Minich J.J., Marotz C., et al. (2019). Contamination in low microbial biomass microbiome studies: Issues and recommendations. Trends Microbiol. 27:105−117. DOI:10.1016/j.tim.2018.11.003 [115] Rajar P., Dhariwal A., Salvadori G., et al. (2022). Microbial DNA extraction of high-host content and low biomass samples: optimized protocol for nasopharynx metagenomic studies. Front. Microbiol. 13:1038120. DOI:10.3389/fmicb.2022.1038120 [116] Clarridge J.E.R. (2004). Impact of 16s rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin. Microbiol. Rev. 17:840−862. DOI:10.1128/CMR.17.4.840-862.2004 [117] Zemanick E.T., Wagner B.D., Robertson C.E., et al. (2017). Airway microbiota across age and disease spectrum in cystic fibrosis. Eur. Respir. J. 50:1700832. DOI:10.1183/13993003.00832-2017 [118] Schneeberger P.H.H., Prescod J., Levy L., et al. (2019). Microbiota analysis optimization for human bronchoalveolar lavage fluid. Microbiome 7:141. DOI:10.1186/s40168-019-0755-x [119] Rodino K.G. and Simner P.J. (2024). Status check: Next-generation sequencing for infectious-disease diagnostics. J. Clin. Invest. 134:e178003. DOI:10.1172/JCI178003 [120] Jia H., Liu H., Tu M., et al. (2023). Diagnostic efficacy of metagenomic next generation sequencing in bronchoalveolar lavage fluid for proven invasive pulmonary aspergillosis. Front. Cell. Infect. Microbiol. 13:1223576. DOI:10.3389/fcimb.2023.1223576 [121] Shi C., Han P., Tang P., et al. (2020). Clinical metagenomic sequencing for diagnosis of pulmonary tuberculosis. J. Infect. 81:567−574. DOI:10.1016/j.jinf.2020.08.004 [122] Jin X., Li J., Shao M., et al. (2022). Improving suspected pulmonary infection diagnosis by bronchoalveolar lavage fluid metagenomic next-generation sequencing: A multicenter retrospective study. Microbiol. Spectr. 10:e247321. DOI:10.1128/spectrum.02473-21 [123] Wang J., Yuan D., Yang X., et al. (2023). Etiology of lower respiratory tract in pneumonia based on metagenomic next-generation sequencing: A retrospective study. Front. Cell. Infect. Microbiol. 13:1291980. DOI:10.3389/fcimb.2023.1291980 [124] Shen H., Liu T., Shen M., et al. (2023). Utilizing metagenomic next-generation sequencing for diagnosis and lung microbiome probing of pediatric pneumonia through bronchoalveolar lavage fluid in pediatric intensive care unit: results from a large real-world cohort. Front. Cell. Infect. Microbiol. 13:1200806. DOI:10.3389/fcimb.2023.1200806 [125] Wang C., Yin X., Ma W., et al. (2024). Clinical application of bronchoalveolar lavage fluid metagenomics next-generation sequencing in cancer patients with severe pneumonia. Respir. Res. 25:68. DOI:10.1186/s12931-023-02654-5 [126] Chen Q., Chen X., Mo P., et al. (2024). Diagnostic values of BALF metagenomic next-generation sequencing, BALF real-time PCR and serum BDG for pneumocystis jirovecii pneumonia in HIV-infected patients. Front. Microbiol. 15:1421660. DOI:10.3389/fmicb.2024.1421660 [127] Peng J., Du B., Qin H., et al. (2021). Metagenomic next-generation sequencing for the diagnosis of suspected pneumonia in immunocompromised patients. J. Infect. 82:22−27. DOI:10.1016/j.jinf.2021.01.029 [128] Combs M.P., Wheeler D.S., Luth J.E., et al. (2021). Lung microbiota predict chronic rejection in healthy lung transplant recipients: A prospective cohort study. Lancet Respir. Med. 9:601−612. DOI:10.1016/S2213-2600(20)30405-7 [129] Wang Y., Yu X., Liu F., et al. (2023). Respiratory microbiota imbalance in children with mycoplasma pneumoniae pneumonia. Emerg. Microbes Infect. 12:2202272. DOI:10.1080/22221751.2023.2202272 [130] Fenn D., Abdel-Aziz M.I., van Oort P.M.P., et al. (2022). Composition and diversity analysis of the lung microbiome in patients with suspected ventilator-associated pneumonia. Crit. Care 26:203. DOI:10.1186/s13054-022-04068-z [131] Wu X., Li Y., Zhang M., et al. (2020). Etiology of severe community-acquired pneumonia in adults based on metagenomic next-generation sequencing: A prospective multicenter study. Infect. Dis. Ther. 9:1003−1015. DOI:10.1007/s40121-020-00353-y [132] Yang A., Chen C., Hu Y., et al. (2022). Application of metagenomic next-generation sequencing (mNGS) using bronchoalveolar lavage fluid (BALF) in diagnosing pneumonia of children. Microbiol. Spectr. 10:e148822. DOI:10.1128/spectrum.01488-22 [133] Wang B., Zhang L., Wang Y., et al. (2022). Alterations in microbiota of patients with covid-19: potential mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 7:143. DOI:10.1038/s41392-022-00986-0 [134] Dickson R.P. (2021). Lung microbiota and covid-19 severity. Nat. Microbiol. 6:1217−1218. DOI:10.1038/s41564-021-00969-x [135] Chen L., Liu W., Zhang Q., et al. (2020). RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg. Microbes Infect. 9:313−319. DOI:10.1080/22221751.2020.1725399 [136] Huang L., Zhang X., Pang L., et al. (2023). Viral reactivation in the lungs of patients with severe pneumonia is associated with increased mortality, a multicenter, retrospective study. J. Med. Virol. 95:e28337. DOI:10.1002/jmv.28337 [137] Ren L., Zhang R., Rao J., et al. (2018). Transcriptionally active lung microbiome and its association with bacterial biomass and host inflammatory status. Msystems 3:e118−e199. DOI:10.1128/mSystems.00199-18 [138] Zhou Z., Ren L., Zhang L., et al. (2020). Heightened innate immune responses in the respiratory tract of covid-19 patients. Cell Host Microbe 27:883−890. DOI:10.1016/j.chom.2020.04.017 [139] Sulaiman I., Chung M., Angel L., et al. (2021). Microbial signatures in the lower airways of mechanically ventilated covid-19 patients associated with poor clinical outcome. Nat. Microbiol. 6:1245−1258. DOI:10.1038/s41564-021-00961-5 [140] Wang L., Cao J., Xia B., et al. (2023). Metatranscriptome of human lung microbial communities in a cohort of mechanically ventilated covid-19 omicron patients. Signal Transduct. Target. Ther. 8:432. DOI:10.1038/s41392-023-01684-1 [141] Zinter M.S., Lindemans C.A., Versluys B.A., et al. (2021). The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury. Blood 137:1679−1689. DOI:10.1182/blood.2020009246 [142] Spottiswoode N., Bloomstein J.D., Caldera S., et al. (2022). Pneumonia surveillance with culture-independent metatranscriptomics in HIV-positive adults in uganda: A cross-sectional study. Lancet Microbe 3:e357−e365. DOI:10.1016/S2666-5247(21)00357-8 [143] Saberi R., Nakhaei M., Fakhar M., et al. (2022). Molecular identification and genotyping of acanthamoeba spp. , in bronchoalveolar lavage fluid from immunocompetent patients with chronic respiratory disorders (CRD). Parasitol. Res. 121:3013−3017. DOI:10.1007/s00436-022-07609-1 [144] Lin C., Ying F., Lai Y., et al. (2019). Use of nested PCR for the detection of trichomonads in bronchoalveolar lavage fluid. BMC Infect. Dis. 19:512. DOI:10.1186/s12879-019-4118-9 [145] Sing A., Leitritz L., Roggenkamp A., et al. (1999). Pulmonary toxoplasmosis in bone marrow transplant recipients: Report of two cases and review. Clin. Infect. Dis. 29:429−433. DOI:10.1086/520228 [146] Demir M., Lang S., Hartmann P., et al. (2022). The fecal mycobiome in non-alcoholic fatty liver disease. J. Hepatol. 76:788−799. DOI:10.1016/j.jhep.2021.11.029 [147] Panaiotov S., Hodzhev Y., Tsafarova B., et al. (2021). Culturable and non-culturable blood microbiota of healthy individuals. Microorganisms 9:1464. DOI:10.3390/microorganisms9071464 [148] Li Z., Wang M., Xu T., et al. (2022). Development and clinical implications of a novel CRISPR-based diagnostic test for pulmonary aspergillus fumigatus infection. J. Microbiol. Immunol. Infect. 55:749−756. DOI:10.1016/j.jmii.2021.11.008 [149] Pang Y., Hu D., Dang Y., et al. (2022). Bronchial artery-pulmonary artery shunt by Apiotrichum mycotoxinivorans infection in a recurrent hemoptysis case. Infect. Drug Resist. 15:4611−4615. DOI:10.2147/IDR.S373615 [150] Murphy S.G., Smith C., Lapierre P., et al. (2023). Direct detection of drug-resistant mycobacterium tuberculosis using targeted next generation sequencing. Front. Public Health 11:1206056. DOI:10.3389/fpubh.2023.1206056 [151] Li S., Tong J., Li H., et al. (2023). L. Pneumophila infection diagnosed by tNGS in a lady with lymphadenopathy. Infect. Drug Resist. 16:4435−4442. DOI:10.2147/IDR.S417495 [152] Li X., Liu Y., Li M., et al. (2023). Epidemiological investigation of lower respiratory tract infections during influenza a (h1n1) pdm09 virus pandemic based on targeted next-generation sequencing. Front. Cell. Infect. Microbiol. 13:1303456. DOI:10.3389/fcimb.2023.1303456 [153] Bhatia S., Pooja and Yadav S.K. (2023). CRISPR-Cas for genome editing: Classification, mechanism, designing and applications. Int. J. Biol. Macromol. 238:124054. DOI:10.1016/j.ijbiomac.2023.124054 [154] Gootenberg J.S., Abudayyeh O.O., Lee J.W., et al. (2017). Nucleic acid detection with CRISPR-Cas13a/c2c2. Science (New York, N.Y.) 356:438−442. DOI:10.1126/science.aam9321 [155] Zhou J., Xiao F., Fu J., et al. (2023). Rapid, ultrasensitive and highly specific diagnosis of mycoplasma pneumoniae by a CRISPR-based detection platform. Front. Cell. Infect. Microbiol. 13:1147142. DOI:10.3389/fcimb.2023.1147142 [156] Lou H., Wang X., Jiang Q., et al. (2024). Clinical evaluation of a highly multiplexed CRISPR-based diagnostic assay for diagnosing lower respiratory tract infection: A prospective cohort study. Infect. Dis. 57:167−177. DOI:10.1080/23744235.2024.2402921 [157] Guo H., Zhao L., Zhu J., et al. (2022). Microbes in lung cancer initiation, treatment, and outcome: boon or bane. Semin. Cancer. Biol. 86:1190−1206. DOI:10.1016/j.semcancer.2021.05.025 [158] Hogea S., Tudorache E., Pescaru C., et al. (2020). Bronchoalveolar lavage: Role in the evaluation of pulmonary interstitial disease. Expert Rev. Respir. Med. 14:1117−1130. DOI:10.1080/17476348.2020.1806063 [159] Yang Q., Qi F., Ye T., et al. (2023). The interaction of macrophages and cd8 t cells in bronchoalveolar lavage fluid is associated with latent tuberculosis infection. Emerg. Microbes Infect. 12:2239940. DOI:10.1080/22221751.2023.2239940 [160] Huang J. and Ren K. (2023). Detection of changes in CEA and ProGRP levels in BALF of patients with peripheral lung cancer and the relationship with CT signs. Contrast Media Mol. Imaging 2023:1421709. DOI:10.1155/2023/1421709 [161] Kim I.A., Hur J.Y., Kim H.J., et al. (2023). A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced NSCLC patients. Transl. Lung Cancer Res. 12:1425−1435. DOI:10.21037/tlcr-22-892 [162] Slimmen L.J.M., Giacalone V.D., Schofield C., et al. (2023). Airway macrophages display decreased expression of receptors mediating and regulating scavenging in early cystic fibrosis lung disease. Front. Immunol. 14:1202009. DOI:10.3389/fimmu.2023.1202009 [163] Nakagome K. and Nagata M. (2020). Possible mechanisms of eosinophil accumulation in eosinophilic pneumonia. Biomolecules 10:638. DOI:10.3390/biom10040638 [164] Todd J.L., Weber J.M., Kelly F.L., et al. (2023). Bal fluid eosinophilia associates with chronic lung allograft dysfunction risk: A multicenter study. Chest 164:670−681. DOI:10.1016/j.chest.2023.03.033 [165] Chen X., Liu F., Zheng B., et al. (2021). Exhausted and apoptotic BALF T cells in proinflammatory airway milieu at acute phase of severe mycoplasma pneumoniae pneumonia in children. Front. Immunol. 12:760488. DOI:10.3389/fimmu.2021.760488 [166] Tasdemir-Yilmaz O.E., Druckenbrod N.R., Olukoya O.O., et al. (2021). Diversity of developing peripheral glia revealed by single-cell RNA sequencing. Dev. Cell 56:2516−2535. DOI:10.1016/j.devcel.2021.08.005 [167] Halpern K.B., Shenhav R., Massalha H., et al. (2018). Paired-cell sequencing enables spatial gene expression mapping of liver endothelial cells. Nat. Biotechnol. 36:962−970. DOI:10.1038/nbt.4231 [168] Subramanian S., Busch C.J., Molawi K., et al. (2022). Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo. Nat. Immunol. 23:458−468. DOI:10.1038/s41590-022-01146-w [169] Wang M., Liu X., Chang G., et al. (2018). Single-cell RNA sequencing analysis reveals sequential cell fate transition during human spermatogenesis. Cell Stem Cell 23:599−614. DOI:10.1016/j.stem.2018.08.007 [170] Bheda P., Aguilar-Gómez D., Becker N.B., et al. (2020). Single-cell tracing dissects regulation of maintenance and inheritance of transcriptional reinduction memory. Mol. Cell 78:915−925. DOI:10.1016/j.molcel.2020.04.016 [171] Liu Y., Wang H., Taylor M., et al. (2022). Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Sci. Immunol. 7:eabl9165. DOI:10.1126/sciimmunol.abl9165 [172] Li X., Kolling F.W., Aridgides D., et al. (2022). ScRNA-seq expression of IFI 27 and APOC 2 identifies four alveolar macrophage superclusters in healthy BALF. Life Sci. Alliance 5:e202201458. DOI:10.26508/lsa.202201458 [173] Bost P., Giladi A., Liu Y., et al. (2020). Host-viral infection maps reveal signatures of severe covid-19 patients. Cell 181:1475−1488. DOI:10.1016/j.cell.2020.05.006 [174] Li H., Wang H., Sokulsky L., et al. (2021). Single-cell transcriptomic analysis reveals key immune cell phenotypes in the lungs of patients with asthma exacerbation. J. Allergy Clin. Immunol. 147:941−954. DOI:10.1016/j.jaci.2020.09.032 [175] Cao C., Memete O., Shao Y., et al. (2022). Single-cell RNA-sequencing reveals epithelial cell signature of multiple subtypes in chemically induced acute lung injury. Int. J. Mol. Sci. 24:277. DOI:10.3390/ijms24010277 [176] Franken A., Van Mol P., Vanmassenhove S., et al. (2022). Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. J. Immunother. Cancer 10 :e5323. DOI: 10.1136/jitc-2022-005323 [177] Wang K.C. and Chang H.Y. (2018). Epigenomics: Technologies and applications. Circ. Res. 122:1191−1199. DOI:10.1161/CIRCRESAHA.118.310998 [178] Vistain L.F. and Tay S. (2021). Single-cell proteomics. Trends Biochem. Sci. 46:661−672. DOI:10.1016/j.tibs.2021.01.013 [179] Zhang X., Xu J., Wang Y., et al. (2023). Respiratory viral infections in the elderly: From the perspective of the aging immune system. Innov. Med. 1:100022. DOI:10.59717/j.xinn-med.2023.100022 [180] Galazzo G., van Best N., Benedikter B.J., et al. (2020). How to count our microbes. The effect of different quantitative microbiome profiling approaches. Front. Cell. Infect. Microbiol. 10:403. DOI:10.3389/fcimb.2020.00403 [181] Li L., Ye Z., Yang S., et al. (2021). Diagnosis of pulmonary nodules by DNA methylation analysis in bronchoalveolar lavage fluids. Clin. Epigenetics 13:185. DOI:10.1186/s13148-021-01163-w [182] Zareba L., Szymanski J., Homoncik Z., et al. (2021). EVs from BALF-mediators of inflammation and potential biomarkers in lung diseases. Int. J. Mol. Sci. 22:3651. DOI:10.3390/ijms22073651 [183] Liu Z., Yan J., Tong L., et al. (2022). The role of exosomes from BALF in lung disease. J. Cell. Physiol. 237:161−168. DOI:10.1002/jcp.30553 [184] Carnino J.M., Lee H. and Jin Y. (2019). Isolation and characterization of extracellular vesicles from broncho-alveolar lavage fluid: A review and comparison of different methods. Respir. Res. 20:240. DOI:10.1186/s12931-019-1210-z [185] Xu R., Greening D.W., Zhu H., et al. (2016). Extracellular vesicle isolation and characterization: toward clinical application. J. Clin. Invest. 126:1152−1162. DOI:10.1172/JCI81129 [186] O'Brien K., Breyne K., Ughetto S., et al. (2020). RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat. Rev. Mol. Cell Biol. 21:585−606. DOI:10.1038/s41580-020-0251-y [187] Sun H., Gao W., Chen R., et al. (2023). CircRNAs in BALF exosomes and plasma as diagnostic biomarkers in patients with acute respiratory distress syndrome caused by severe pneumonia. Front. Cell. Infect. Microbiol. 13:1194495. DOI:10.3389/fcimb.2023.1194495 [188] Kaur G., Maremanda K.P., Campos M., et al. (2021). Distinct exosomal miRNA profiles from BALF and lung tissue of COPD and IPF patients. Int. J. Mol. Sci. 22:11830. DOI:10.3390/ijms222111830 [189] Aksoy M.O., Kim V., Cornwell W.D., et al. (2017). Secretion of the endoplasmic reticulum stress protein, grp78, into the BALF is increased in cigarette smokers. Respir. Res. 18:78. DOI:10.1186/s12931-017-0561-6 [190] Testa A., Venturelli E. and Brizzi M.F. (2021). Extracellular vesicles as a novel liquid biopsy-based diagnosis for the central nervous system, head and neck, lung, and gastrointestinal cancers: Current and future perspectives. Cancers 13:2792. DOI:10.3390/cancers13112792 [191] Sathe N.A., Morrell E.D., Bhatraju P.K., et al. (2023). Alveolar biomarker profiles in subphenotypes of the acute respiratory distress syndrome. Crit. Care Med. 51:e13−e18. DOI:10.1097/CCM.0000000000005704 [192] Kim I.A., Hur J.Y., Kim H.J., et al. (2022). Extracellular vesicle-based bronchoalveolar lavage fluid liquid biopsy for EGFR mutation testing in advanced non-squamous NSCLC. Cancers 14:2744. DOI:10.3390/cancers14112744 [193] Hur J.Y., Kim H.J., Lee J.S., et al. (2018). Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. Mol. Cancer 17:15. DOI:10.1186/s12943-018-0772-6 [194] Shaba E., Landi C., Carleo A., et al. (2021). Proteome characterization of BALF extracellular vesicles in idiopathic pulmonary fibrosis: Unveiling undercover molecular pathways. Int. J. Mol. Sci. 22:5696. DOI:10.3390/ijms22115696 [195] Yu W., He Y., Shang Y., et al. (2023). Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis. Clin. Immunol. 247:109230. DOI:10.1016/j.clim.2023.109230 [196] Lee H., Groot M., Pinilla-Vera M., et al. (2019). Identification of miRNA-rich vesicles in bronchoalveolar lavage fluid: Insights into the function and heterogeneity of extracellular vesicles. J. Control. Release 294:43−52. DOI:10.1016/j.jconrel.2018.12.008 [197] Holtzman J. and Lee H. (2020). Emerging role of extracellular vesicles in the respiratory system. Exp. Mol. Med. 52:887−895. DOI:10.1038/s12276-020-0450-9 [198] Yang Q., Luo Y., Ge P., et al. (2023). Emodin ameliorates severe acute pancreatitis-associated acute lung injury in rats by modulating exosome-specific miRNA expression profiles. Int. J. Nanomed. 18:6743−6761. DOI:10.2147/IJN.S428924 [199] Huang J., Ding M., Lu Y., et al. (2023). MiR-1246b, a novel miRNA molecule of extracellular vesicles in bronchoalveolar lavage fluid, promotes nodule growth through FGF14 in patients with lung cancer. Cell Death Dis. 14:789. DOI:10.1038/s41419-023-06218-9 [200] Lee H., Hong R. and Jin Y. (2024). Altered circular RNA expressions in extracellular vesicles from bronchoalveolar lavage fluids in mice after bacterial infections. Front. Immunol. 15:1354676. DOI:10.3389/fimmu.2024.1354676 [201] Chen W., Xu J., Wu Y., et al. (2023). The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis. Int. J. Biol. Sci. 19:2879−2896. DOI:10.7150/ijbs.84994 [202] Tang R., Hu Y., Mei S., et al. (2023). Non-coding RNA alterations in extracellular vesicles from bronchoalveolar lavage fluid contribute to mechanical ventilation-induced pulmonary fibrosis. Front. Immunol. 14:1141761. DOI:10.3389/fimmu.2023.1141761 [203] Luo H., Xiao T., Sun X., et al. (2023). The regulation of circRNA_kif26b on alveolar epithelial cell senescence via miR-346-3p is involved in microplastics-induced lung injuries. Sci. Total Environ. 882:163512. DOI:10.1016/j.scitotenv.2023.163512 [204] Slebos D., Scholma J., Boezen H.M., et al. (2002). Longitudinal profile of bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation. Am. J. Respir. Crit. Care Med. 165:501−507. DOI:10.1164/ajrccm.165.4.2107035 [205] Takei R., Arita M., Kumagai S., et al. (2017). Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. BMC Pulm. Med. 17:67. DOI:10.1186/s12890-017-0412-8 [206] Hellyer T.P., Morris A.C., Mcauley D.F., et al. (2015). Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia. Thorax 70:41−47. DOI:10.1136/thoraxjnl-2014-205766 [207] Hellyer T.P., Mcauley D.F., Walsh T.S., et al. (2020). Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (vaprapid2): A randomised controlled trial and process evaluation. Lancet Respir. Med. 8:182−191. DOI:10.1016/S2213-2600(19)30367-4 [208] Hoser G., Domagała-Kulawik J., Droszcz P., et al. (2003). Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: A flow cytometry analysis of bronchoalveolar lavage fluid cells. Med. Sci. Monit. 9:BR310−BR315. [209] Rossides M., Darlington P., Kullberg S., et al. (2023). Sarcoidosis: Epidemiology and clinical insights. J. Intern. Med. 293:668−680. DOI:10.1111/joim.13629 [210] Wauters E., Van Mol P., Garg A.D., et al. (2021). Discriminating mild from critical covid-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res. 31:272−290. DOI:10.1038/s41422-020-00455-9 [211] King A. (2024). Exploring the lung microbiome's role in disease. Nature DOI: 10.1038/d41586-024-01123-3 [212] Lal C.V., Travers C., Aghai Z.H., et al. (2016). The airway microbiome at birth. Sci. Rep. 6:31023. DOI:10.1038/srep31023 [213] Toivonen L., Hasegawa K., Waris M., et al. (2019). Early nasal microbiota and acute respiratory infections during the first years of life. Thorax 74:592−599. DOI:10.1136/thoraxjnl-2018-212629 [214] Wu B.G., Sulaiman I., Tsay J.J., et al. (2021). Episodic aspiration with oral commensals induces a myd88-dependent, pulmonary T-helper cell type 17 response that mitigates susceptibility to streptococcus pneumoniae. Am. J. Respir. Crit. Care Med. 203:1099−1111. DOI:10.1164/rccm.202005-1596OC [215] Sun W., Zheng L., Kang L., et al. (2024). Comparative analysis of metagenomic and targeted next-generation sequencing for pathogens diagnosis in bronchoalveolar lavage fluid specimens. Front. Cell. Infect. Microbiol. 14:1451440. DOI:10.3389/fcimb.2024.1451440 [216] Sun Y., Liu Y., Li J., et al. (2023). Characterization of lung and oral microbiomes in lung cancer patients using culturomics and 16s rRNA gene sequencing. Microbiol. Spectr. 11:e31423. DOI:10.1128/spectrum.00314-23 [217] Xue M., Zhang T., Lin R., et al. (2022). Clinical utility of heparin-binding protein as an acute-phase inflammatory marker in interstitial lung disease. J. Leukoc. Biol. 112:861−873. DOI:10.1002/JLB.3MA1221-489R [218] Lin W., Lin C., Chen C., et al. (2010). Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators. Exp. Biol. Med. (Maywood) 235:57−65. DOI:10.1258/ebm.2009.009256 [219] Larsen E.L., Nilius H., Studt J., et al. (2024). Accuracy of diagnosing heparin-induced thrombocytopenia. Jama Netw. Open 7:e243786. DOI:10.1001/jamanetworkopen.2024.3786 [220] Dong X., Xu X., Huang Y., et al. (2023). Prognostic value of secretory autophagosomes in patients with acute respiratory distress syndrome. Biomark. Res. 11:79. DOI:10.1186/s40364-023-00519-z [221] Li Y., He Y., Chen S., et al. (2022). S100a12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis. Front. Immunol. 13:810338. DOI:10.3389/fimmu.2022.810338 [222] Ji J., Zheng S., Liu Y., et al. (2023). Increased expression of OPN contributes to idiopathic pulmonary fibrosis and indicates a poor prognosis. J. Transl. Med. 21:640. DOI:10.1186/s12967-023-04279-0 [223] Fisher A.J., Donnelly S.C., Hirani N., et al. (2001). Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am. J. Respir. Crit. Care Med. 163:259−265. [224] Ruppert A., Baud L., Rabbe N., et al. (2019). Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. Bull. Cancer 106:179−188. DOI:10.1016/j.bulcan.2018.11.014 [225] Chang C., Armstrong D., Corry D.B., et al. (2023). Alveolar macrophages in lung cancer: opportunities challenges. Front. Immunol. 14:1268939. DOI:10.3389/fimmu.2023.1268939 [226] Xue Y., Chen Y., Sun S., et al. (2024). Tet2-stat3-cxcl5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition. J. Exp. Med. 221:e20240111. DOI:10.1084/jem.20240111 [227] Tian Y., Li M., Song W., et al. (2019). Effects of probiotics on chemotherapy in patients with lung cancer. Oncol. Lett. 17:2836−2848. DOI:10.3892/ol.2019.9906 [228] Katayama Y., Yamada T., Shimamoto T., et al. (2019). The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. Transl. Lung Cancer Res. 8:847−853. DOI:10.21037/tlcr.2019.10.23 [229] Zhang L., Jin Q., Chai D., et al. (2022). The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors. Front. Pharmacol. 13:937874. DOI:10.3389/fphar.2022.937874 [230] Shenoy A.T., Lyon De Ana C., Arafa E.I., et al. (2021). Antigen presentation by lung epithelial cells directs cd4(+) t(rm) cell function and regulates barrier immunity. Nat. Commun. 12:5834. DOI:10.1038/s41467-021-26045-w [231] Mondoni M., Rinaldo R.F., Carlucci P., et al. (2022). Bronchoscopic sampling techniques in the era of technological bronchoscopy. Pulmonology 28:461−471. DOI:10.1016/j.pulmoe.2020.06.007 [232] Lerner A.D. and Feller-Kopman D. (2017). Bronchoscopic techniques used in the diagnosis and staging of lung cancer. J. Natl. Compr. Canc. Netw. 15:640−647. DOI:10.6004/jnccn.2017.0065 [233] Sung J.Y., Hwang Y., Shin M.H., et al. (2018). Utility of conventional culture and MALDI-TOF MS for identification of microbial communities in bronchoalveolar lavage fluid in comparison with the GS junior next generation sequencing system. Ann. Lab. Med. 38:110−118. DOI:10.3343/alm.2018.38.2.110 [234] Criner G.J., Eberhardt R., Fernandez-Bussy S., et al. (2020). Interventional bronchoscopy. Am. J. Respir. Crit. Care Med. 202:29−50. DOI:10.1164/rccm.201907-1292SO [235] Baysoy A., Bai Z., Satija R., et al. (2023). The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 24:695−713. DOI:10.1038/s41580-023-00615-w [236] Aggarwal N., Kitano S., Puah G.R.Y., et al. (2023). Microbiome and human health: Current understanding, engineering, and enabling technologies. Chem. Rev. 123:31−72. DOI:10.1021/acs.chemrev.2c00431 [237] Cullin N., Azevedo Antunes C., Straussman R., et al. (2021). Microbiome and cancer. Cancer Cell 39:1317−1341. DOI:10.1016/j.ccell.2021.08.006 [238] Hilty M., Burke C., Pedro H., et al. (2010). Disordered microbial communities in asthmatic airways. Plos One 5:e8578. DOI:10.1371/journal.pone.0008578 [239] Aagaard K., Ma J., Antony K.M., et al. (2014). The placenta harbors a unique microbiome. Sci. Transl. Med. 6:237ra65. DOI:10.1126/scitranslmed.3008599 [240] Chang D., Dela Cruz C.S. and Sharma L. (2020). Challenges in understanding lung microbiome: It is not like the gut microbiome. Respirology (Carlton, Vic.) 25:244−245. DOI:10.1111/resp.13759 [241] Yan Z., Chen B., Yang Y., et al. (2022). Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions. Nat. Microbiol. 7:1361−1375. DOI:10.1038/s41564-022-01196-8 [242] Chotirmall S.H., Bogaert D., Chalmers J.D., et al. (2022). Therapeutic targeting of the respiratory microbiome. Am. J. Respir. Crit. Care Med. 206:535−544. DOI:10.1164/rccm.202112-2704PP [243] de Vos W.M., Tilg H., Van Hul M., et al. (2022). Gut microbiome and health: mechanistic insights. Gut 71:1020−1032. DOI:10.1136/gutjnl-2021-326789 [244] Yagi K., Huffnagle G.B., Lukacs N.W., et al. (2021). The lung microbiome during health and disease. Int. J. Mol. Sci. 22:10872. DOI:10.3390/ijms221910872 [245] Dickson R.P., Martinez F.J. and Huffnagle G.B. (2014). The role of the microbiome in exacerbations of chronic lung diseases. Lancet 384:691−702. DOI:10.1016/S0140-6736(14)61136-3 [246] Li R., Li J. and Zhou X. (2024). Lung microbiome: New insights into the pathogenesis of respiratory diseases. Signal Transduct. Target. Ther. 9:19. DOI:10.1038/s41392-023-01722-y [247] Rogers G.B., Shaw D., Marsh R.L., et al. (2015). Respiratory microbiota: Addressing clinical questions, informing clinical practice. Thorax 70:74−81. DOI:10.1136/thoraxjnl-2014-205826 [248] Yuan X., Xie L., Shi Z., et al. (2023). Application of mNGS in the study of pulmonary microbiome in pneumoconiosis complicated with pulmonary infection patients and exploration of potential biomarkers. Front. Cell. Infect. Microbiol. 13:1200157. DOI:10.3389/fcimb.2023.1200157 [249] Puschhof J. and Elinav E. (2023). Human microbiome research: Growing pains and future promises. Plos Biol. 21:e3002053. DOI:10.1371/journal.pbio.3002053 [250] Hosang L., Canals R.C., van der Flier F.J., et al. (2022). The lung microbiome regulates brain autoimmunity. Nature 603:138−144. DOI:10.1038/s41586-022-04427-4 [251] Achouiti A., Vogl T., Endeman H., et al. (2014). Myeloid-related protein-8/14 facilitates bacterial growth during pneumococcal pneumonia. Thorax 69:1034−1042. DOI:10.1136/thoraxjnl-2014-205668 [252] Awasthi S., Magee D.M. and Coalson J.J. (2004). Coccidioides posadasii infection alters the expression of pulmonary surfactant proteins (SP)-A and SP-D. Respir. Res. 5:28. DOI:10.1186/1465-9921-5-28 [253] Whiteside S.A., Mcginniss J.E. and Collman R.G. (2021). The lung microbiome: Progress and promise. J. Clin. Invest. 131:e150473. DOI:10.1172/JCI150473 [254] Mortaz E., Adcock I.M., Folkerts G., et al. (2013). Probiotics in the management of lung diseases. Mediat. Inflamm. 2013:751068. DOI:10.1155/2013/751068 [255] Wang Q. and Liu S. (2023). The effects and pathogenesis of PM2.5 and its components on chronic obstructive pulmonary disease. Int. J. Chronic Obstr. Pulm. Dis. 18 :493-506. DOI: 10.2147/COPD.S402122 [256] Li J., Hu Y., Liu L., et al. (2020). PM2.5 exposure perturbs lung microbiome and its metabolic profile in mice. Sci. Total Environ. 721 :137432. DOI: 10.1016/j.scitotenv.2020.137432 [257] de Toro-Martín J., Arsenault B.J., Després J., et al. (2017). Precision nutrition: A review of personalized nutritional approaches for the prevention and management of metabolic syndrome. Nutrients 9:913. DOI:10.3390/nu9080913 [258] Wang J., Ghosh D. and Maniruzzaman M. (2023). Using bugs as drugs: Administration of bacteria-related microbes to fight cancer. Adv. Drug Deliv. Rev. 197:114825. DOI:10.1016/j.addr.2023.114825 [259] Cao Y., Xia H., Tan X., et al. (2024). Intratumoural microbiota: A new frontier in cancer development and therapy. Signal Transduct. Target. Ther. 9:15. DOI:10.1038/s41392-023-01693-0 [260] Nejman D., Livyatan I., Fuks G., et al. (2020). The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science (New York, N.Y.) 368:973−980. DOI:10.1126/science.aay9189 [261] Wang S., Yao X., Ma S., et al. (2021). A single-cell transcriptomic landscape of the lungs of patients with covid-19. Nat. Cell Biol. 23:1314−1328. DOI:10.1038/s41556-021-00796-6 [262] Fang C., Mei J., Tian H., et al. (2020). CSF3 is a potential drug target for the treatment of covid-19. Front. Physiol. 11:605792. DOI:10.3389/fphys.2020.605792 [263] Shawaf T., Schuberth H. and Hussen J. (2022). Immune cell composition of the bronchoalveolar lavage fluid in healthy and respiratory diseased dromedary camels. BMC Vet. Res. 18:353. DOI:10.1186/s12917-022-03446-7 [264] Ergan B. and Nava S. (2018). The use of bronchoscopy in critically ill patients: Considerations and complications. Expert Rev. Respir. Med. 12:651−663. DOI:10.1080/17476348.2018.1494576 [265] Yu Y., Liu C., Zhang Z., et al. (2019). Bronchoalveolar lavage fluid dilution in ICU patients: What we should know and what we should do. Crit. Care 23:23. DOI:10.1186/s13054-018-2300-x [266] Meyer K.C. and Raghu G. (2011). Bronchoalveolar lavage for the evaluation of interstitial lung disease: Is it clinically useful. Eur. Respir. J. 38:761−769. DOI:10.1183/09031936.00069509 [267] Zhang H., Wang N., Xu Y., et al. (2023). Comparative analysis of peripheral blood immunoinflammatory landscapes in patients with acute cholangitis and its secondary septic shock using single-cell RNA sequencing. Biochem. Biophys. Res. Commun. 683:149121. DOI:10.1016/j.bbrc.2023.149121 [268] Crowley E., Di Nicolantonio F., Loupakis F., et al. (2013). Liquid biopsy: Monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10:472−484. DOI:10.1038/nrclinonc.2013.110 [269] Chen C.K., Liao J., Li M.S., et al. (2020). Urine biopsy technologies: Cancer and beyond. Theranostics 10:7872−7888. DOI:10.7150/thno.44634 [270] Kaczor-Urbanowicz K.E., Wei F., Rao S.L., et al. (2019). Clinical validity of saliva and novel technology for cancer detection. Biochim. Biophys. Acta Rev. Cancer 1872:49−59. DOI:10.1016/j.bbcan.2019.05.007 [271] Nonaka T. and Wong D.T.W. (2022). Saliva diagnostics. Ann. Rev. Anal. Chem. (Palo Alto, Calif.) 15:107−121. DOI:10.1146/annurev-anchem-061020-123959 [272] Kim C.K. and Hagan J.B. (2004). Sputum tests in the diagnosis and monitoring of asthma. Ann. Allergy Asthma Immunol. 93 :112-122, 122-124, 184. DOI: 10.1016/S1081-1206(10)61462-7 [273] Scheja A., Larsen K., Todorova L., et al. (2007). BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis. Eur. Respir. J. 29:446−452. DOI:10.1183/09031936.00135205 [274] Mei J., Tian H., Huang H., et al. (2021). Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. Cell Prolif. 54:e13029. DOI:10.1111/cpr.13029 [275] In T Veld S.G.J.G., Arkani M., Post E., et al. (2022). Detection and localization of early- and late-stage cancers using platelet RNA. Cancer Cell 40:999−1009. DOI:10.1016/j.ccell.2022.08.006 [276] Reggiardo R.E., Maroli S.V., Peddu V., et al. (2023). Profiling of repetitive RNA sequences in the blood plasma of patients with cancer. Nat. Biomed. Eng. 7:1627−1635. DOI:10.1038/s41551-023-01081-7 [277] Mei J., Tian H., Huang H.S., et al. (2023). Ccne1 is a potential target of metformin for tumor suppression of ovarian high-grade serous carcinoma. Cell Cycle 22:85−99. DOI:10.1080/15384101.2022.2109362 [278] Larsen G.L., Presley D.M., Graves J.P., et al. (1991). The effect of intravascular complement activation and brief episodes of hypoxia on protein in bronchoalveolar lavage fluid in c5 sufficient and deficient mice. Pediatr. Pulmonol. 11:302−309. DOI:10.1002/ppul.1950110406 [279] Zeng D., Wang C., Mu C., et al. (2021). Cell-free DNA from bronchoalveolar lavage fluid (BALF): A new liquid biopsy medium for identifying lung cancer. Ann. Transl. Med. 9:1080. DOI:10.21037/atm-21-2579 [280] Kang Y.P., Lee W.J., Hong J.Y., et al. (2014). Novel approach for analysis of bronchoalveolar lavage fluid (BALF) using HPLC-QTOF-MS-based lipidomics: Lipid levels in asthmatics and corticosteroid-treated asthmatic patients. J. Proteome Res. 13:3919−3929. DOI:10.1021/pr5002059 [281] Zheng L., Liu C., Wang H., et al. (2024). Intact lung tissue and bronchoalveolar lavage fluid are both suitable for the evaluation of murine lung microbiome in acute lung injury. Microbiome 12:56. DOI:10.1186/s40168-024-01772-6 [282] Erturk-Hasdemir D. and Kasper D.L. (2018). Finding a needle in a haystack: Bacteroides fragilis polysaccharide a as the archetypical symbiosis factor. Ann. N. Y. Acad. Sci. 1417:116−129. DOI:10.1111/nyas.13660 [283] Fu A., Yao B., Dong T., et al. (2022). Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185:1356−1372. DOI:10.1016/j.cell.2022.02.027 [284] Qiu L., Lu W., Tu C., et al. (2023). Evidence of microplastics in bronchoalveolar lavage fluid among never-smokers: A prospective case series. Environ. Sci. Technol. 57:2435−2444. DOI:10.1021/acs.est.2c06880 [285] Wu P., Chan C., Tan H., et al. (2024). A threat or not? A global-scale investigation on microplastics inhalation during the first-ever worldwide face-mask wearing against the covid-19 pandemic. Innov. Med. 2 :100097. DOI: 10.59717/j.xinn-med.2024.100097 [286] Chen Q., Wei X., Xie R., et al. (2024). Beyond physical particles: A holistic assessment of human health risks from real-world micro-nanoplastic exposure. Innov. Med. 2:100104. DOI:10.59717/j.xinn-med.2024.100104 [287] Du T., Yu X., Shao S., et al. (2023). Aging of nanoplastics significantly affects protein corona composition thus enhancing macrophage uptake. Environ. Sci. Technol. 57:3206−3217. DOI:10.1021/acs.est.2c05772 [288] Hu Q., Bian Q., Rong D., et al. (2023). Jak/stat pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. Front. Bioeng. Biotechnol. 11:1110765. DOI:10.3389/fbioe.2023.1110765 -
ABOUT THIS ARTICLE
Cite this article:
Mei J., Chen Y.-S., Tian H.-X., et al. (2025). Bronchoalveolar lavage fluid (BALF): Clinical applications for present and future. The Innovation Medicine 3:100115. https://doi.org/10.59717/j.xinn-med.2025.100115
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Figures(4)
Article Metrics
Relative Articles
Cited by
Export File
Citation
Mei J., Chen Y.-S., Tian H.-X., et al. (2025). Bronchoalveolar lavage fluid (BALF): Clinical applications for present and future. The Innovation Medicine 3:100115. https://doi.org/10.59717/j.xinn-med.2025.100115
Format
Content
-
Figure 1.
Clinical value of BALF
-
Figure 2.
The history of BALF collection
-
Figure 3.
The applications of BALF in clinical detection
-
Figure 4.
Future clinical applications of BALF
Twitter